In a pioneering advancement, Chinese scientists achieved a clinical breakthrough for type 1 diabetes by successfully transplanting islet cells into a female patient, potentially reversing the disease. This world-first procedure involved injecting the patient with stem cells derived from her own body, as detailed in the journal Cell.
A collaborative team from Tianjin First Central Hospital, Peking University, Changping Laboratory, and Hangzhou Reprogenix Bioscience conducted the first-of-its-kind treatment.
Type 1 diabetes typically manifests in childhood and involves the immune system attacking the pancreas, impairing insulin-producing islet cells.
Previously, the only long-term remedy was a pancreas transplant, while most patients managed their condition short-term with insulin injections. Recent research has highlighted stem cells’ potential to cure this condition by differentiating into various cell types, as reported by Independent UK.
This trial involved extracting cells from a 25-year-old patient from Tianjin, reverting them to a pluripotent state, and then transplanting islet cells derived from these stem cells.
The patient, suffering from type 1 diabetes for 11 years and heavily reliant on insulin, experienced restored blood sugar control post-transplant.
Wang Shusen from Tianjin First Central Hospital stated that while traditional islet transplant therapy offers benefits, its use is restricted by the scarcity of pancreatic donors.
Seventy-five days following the procedure, the patient ceased needing insulin injections and maintained normal diabetes indicators for over a year, achieving what the study describes as a clinical cure.
The researchers noted that the procedure restored glycemic control and functionally reversed her diabetes without transplant-related abnormalities. Despite the success, they cautioned that long-term monitoring is necessary to ensure the treatment’s efficacy, especially since the patient was also receiving immunosuppressive drugs for a previous liver transplant.
The team has called for additional clinical trials to explore stem cell transplantation’s potential in reversing type 1 diabetes.
